Improving peptide relative quantification in MALDI-TOF MS for biomarker assessment

Proteomics

Volumn 13, Issue 20, 2013, Pages 2967-2975

  Albalat, Amaya ^a   Stalmach, Angelique ^a   Bitsika, Vasiliki ^b   Siwy, Justyna ^c,d   Schanstra, Joost P ^e   Petropoulos, Alexandros D ^b   Vlahou, Antonia ^b   Jankowski, Joachim ^d   Persson, Frederik ^f   Rossing, Peter ^f   Jaskolla, Thorsten W ^g   Mischak, Harald ^a,c   Husi, Holger ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Academy of Athens Biomedical Research Foundation   (Greece)

^c MOSAIQUES DIAGNOSTICS GMBH   (Germany)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^e University Hospital of Toulouse   (France)

^f STENO DIABETES CENTER   (Denmark)

^g UNIVERSITY OF MÜNSTER   (Germany)

Author keywords

Biomarker; MALDI TOF MS; Proteomic profiling; Relative quantification; Technology; Urine

Indexed keywords

BIOLOGICAL MARKER;

ALGORITHM; ANALYTIC METHOD; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DILUTION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MACROALBUMINURIA; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; PEPTIDE ANALYSIS; PRIORITY JOURNAL; PROTEOMICS; QUANTITATIVE ANALYSIS; REPRODUCIBILITY;

BIOMARKER; MALDI-TOF MS; PROTEOMIC PROFILING; RELATIVE QUANTIFICATION; TECHNOLOGY; URINE;

ALBUMINURIA; AMINO ACID SEQUENCE; BIOLOGICAL MARKERS; DIABETES MELLITUS, TYPE 1; HUMANS; MOLECULAR SEQUENCE DATA; PEPTIDES; REGRESSION ANALYSIS; REPRODUCIBILITY OF RESULTS; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84885417510     PISSN: 16159853     EISSN: 16159861     Source Type: Journal    
DOI: 10.1002/pmic.201300100     Document Type: Article

References (32)

1. Gao, X., Tan, B. H., Sugrue, R., Tang, K., MALDI mass spectrometry for nucleic acid analysis. Top. Curr. Chem. 2013, 331, 55-77.
2. Wang, H., Zhao, Z., Guo, Y., Chemical and biochemical applications of MALDI TOF-MS based on analyzing the small organic compounds. Top. Curr. Chem. 2013, 331, 165-192.
3. Fuchs, B., Analysis of phospolipids and glycolipids by thin-layer chromatography-matrix-assisted laser desorption and ionization mass spectrometry. J. Chromatogr. A 2012, 1259, 62-73.
4. Lapolla, A., Seraglia, R., Molin, L., Williams, K. etal., Low molecular weight proteins in urines from healthy subjects as well as diabetic, nephropathic and diabetic-nephropathic patients: a MALDI study. J. Mass Spectrom. 2009, 44, 419-425.
5. Lu, M., Cai, Z., Advances of MALDI-TOF MS in the analysis of traditional Chinese medicines. Top. Curr. Chem. 2013, 331, 143-164.
6. Sandrin, T. R., Goldstein, J. E., Schumaker, S., MALDI TOF MS profiling of bacteria at the strain level: a review. Mass Spectrom. Rev. 2012, 32, 188-217.
7. Lee, Y. J., Perdian, D. C., Song, Z., Yeung, E. S., Nikolau, B. J., Use of mass spectrometry for imaging metabolites in plants. Plant J. 2012, 70, 81-95.
8. Bryan, R. T., Wei, W., Shimwell, N. J., Collins, S. I. etal., Assessment of high-throughput high-resolution MALDI-TOF-MS of urinary peptides for the detection of muscle-invasive bladder cancer. Proteomics Clin. Appl. 2011, 5, 493-503.
9. M'Koma, A. E., Seeley, E. H., Washington, M. K., Schwartz, D. A. etal., Proteomic profiling of mucosal and submucosal colonic tissues yields protein signatures that differentiate the inflammatory colitides. Inflamm. Bowel Dis. 2011, 17, 875-883.
10. Albrethsen, J., The first decade of MALDI protein profiling: a lesson in translational biomarker research. J. Proteomics 2011, 74, 765-773.
11. Giebel, R., Worden, C., Rust, S. M., Kleinheinz, G. T. etal., Chapter 6 - microbial fingerprinting using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF MS): applications and challenges. Adv. Appl. Microbiol. 2010, 71, 149-184.
12. van Winden, A., Gast, M. C., Beijnen, J., Rutgers, E. etal., Validation of previously identified serum biomarkers for breast cancer with SELDI-TOF MS: a case control study. BMC Med. Genomics 2009, 19, 4. DOI: 10.1186/1755-8794-2-4.
13. Engwegen, J. Y. M. N., Mehra, N., Haanen, J. B. A. G., Bonfrer, J. M. G. etal., Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations. Lab. Invest. 2007, 87, 161-172.
14. Szajli, E., Feher, T., Medzihradszky, K. F., Investigating the quantitative nature of MALDI-TOF MS. Mol. Cell. Proteomics 2008, 7, 2410-2418.
15. Gorka, J., Bahr, U., Karas, M., Graphite supported preparation (GSP) of alpha-cyano-4-hydroxycinnamic acid (CHCA) for matrix-assisted laser desorption/ionisation mass spectrometry (MALDI-MS) for peptides and proteins. J. Am. Soc. Mass Spectrom. 2012, 23, 1949-1954.
16. Jaskolla, T. W., Lehmann, W. D., Karas, M., 4-Chloro-apha-cyanocinnamic acid is an advanced, rationally designed MALDI matrix. Proc. Natl. Acad. Sci. USA 2008, 105, 12200-12205.
17. Pan, C., Xu, B., Zhou, M., Fu, Y. etal., Recent developments in methods and technology for analysis of biological samples by MALDI-TOF-MS. Anal. Bioanal. Chem. 2007, 387, 193-204.
18. Vestal, M. L., Modern MALDI time-of-flight mass spectrometry. J. Mass Spectrom. 2009, 44, 303-317.
19. Zerefos, P., Prados, J., Kossida, S., Kalousis, A., Vlahou, A., Sample preparation and bioinformatics in MALDI profiling of urinary proteins. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2007, 853, 20-30.
20. Mischak, H., Kolch, W., Aivaliotis, M., Bouyssie, D. etal., Comprehensive human urine standards for comparability and standardization in clinical proteome analysis. Proteomics Clin. Appl. 2010, 4, 464-478.
21. Levey, A. S., Bosch, J. P., Lewis, J. B., Greene, T. etal., A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of diet in renal disease study group. Ann. Intern. Med. 1999, 160, 461-470.
22. Theodorescu, D., Fliser, D., Wittke, S., Mischak, H. etal., Pilot study of capillary electrophoresis coupled to mass spectrometry as a tool to define potential prostate cancer biomarkers in urine. Electrophoresis 2005, 26, 2797-2808.
23. Molin, L., Seraglia, R., Lapolla, A., Ragazzi, E. etal., A comparison between MALDI-MS and CE-MS data for biomarker assessment in chronic kidney diseases. J. Proteomics 2012, 75, 5888-5897.
24. Siwy, J., Mullen, W., Golovko, I., Franke, J., Zurbig, P., Human urinary peptide database for multiple disease biomarker discovery. Proteomics Clin. Appl. 2011, 5, 367-374.
25. Benjamini, Y., Hochberg, Y., Controlling the false discovery rate: a practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B 1995, 57, 289-300.
26. Alkhalaf, A., Zurbig, P., Bakker, S. J. L., Bilo, H. J. G. etal., Multicentric validation of proteomic biomarkers in urine specific for diabetic nephropathy. PLoS ONE 2010, 5, e13421.
27. Zhang, X., Shi, L., Shu, S., Wang, Y. etal., An improved method of sample preparation on AnchorChip targets for MALDI-MS and MS/MS and its application in the liver proteome project. Proteomics 2007, 7, 2340-2349.
28. Albrethsen, J., Reproducibility in protein profiling by MALDI-TOF mass spectrometry. Clin. J. Am. Soc. Nephrol. 2007, 53, 852-858.
29. Duncan, M. W., Roder, H., Hunsucker, S. W., Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Brief Funct. Genomic Proteomic 2008, 7, 355-370.
30. Duncan, M. W., Roder, H., Hunsucker, S. W., Quantitative matrix-assisted laser desorption/ionization mass spectrometry. Brief Funct. Genomic Proteomic 2008, 7, 355-370.
31. Good, D. M., Zurbig, P., Dakna, M., Dominiczak, A. F. etal., Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol. Cell. Proteomics 2010, 9, 2424-2437.
32. Rossing, K., Mischak, H., Dakna, M., Zurbig, P. etal., Urinary proteomics in diabetes and CKD. J. Am. Soc. Nephrol. 2008, 19, 1283-1290.